BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27195818)

  • 1. Is it Fabry disease?
    Schiffmann R; Fuller M; Clarke LA; Aerts JM
    Genet Med; 2016 Dec; 18(12):1181-1185. PubMed ID: 27195818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review.
    Effraimidis G; Rasmussen ÅK; Bundgaard H; Sørensen SS; Feldt-Rasmussen U
    J Inherit Metab Dis; 2020 Sep; 43(5):922-933. PubMed ID: 32246457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.
    Kobayashi M; Ohashi T; Fukuda T; Yanagisawa T; Inomata T; Nagaoka T; Kitagawa T; Eto Y; Ida H; Kusano E
    Mol Genet Metab; 2012 Dec; 107(4):711-5. PubMed ID: 23146289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaperone Therapy in Fabry Disease.
    Weidemann F; Jovanovic A; Herrmann K; Vardarli I
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field.
    Sorriento D; Iaccarino G
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
    Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
    J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
    De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
    Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
    Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of Fabry disease in patients with common heart disease.
    Schiffmann R; Swift C; McNeill N; Benjamin ER; Castelli JP; Barth J; Sweetman L; Wang X; Wu X
    Genet Med; 2018 Jul; 20(7):754-759. PubMed ID: 29227985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
    Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
    J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.
    Oikawa M; Sakamoto N; Kobayashi A; Suzuki S; Yoshihisa A; Yamaki T; Nakazato K; Suzuki H; Saitoh S; Kiko Y; Nakano H; Hayashi T; Kimura A; Takeishi Y
    BMC Cardiovasc Disord; 2016 May; 16():83. PubMed ID: 27160240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
    PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of two alpha-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease.
    Kase R; Bierfreund U; Klein A; Kolter T; Utsumi K; Itoha K; Sandhoff K; Sakuraba H
    Biochim Biophys Acta; 2000 Jun; 1501(2-3):227-35. PubMed ID: 10838196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.
    Schiffmann R; Forni S; Swift C; Brignol N; Wu X; Lockhart DJ; Blankenship D; Wang X; Grayburn PA; Taylor MR; Lowes BD; Fuller M; Benjamin ER; Sweetman L
    J Am Heart Assoc; 2014 Feb; 3(1):e000394. PubMed ID: 24496231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
    Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
    Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation impact on Fabry disease.
    Di Risi T; Vinciguerra R; Cuomo M; Della Monica R; Riccio E; Cocozza S; Imbriaco M; Duro G; Pisani A; Chiariotti L
    Clin Epigenetics; 2021 Feb; 13(1):24. PubMed ID: 33531072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between GLA variants and alpha-Galactosidase A profile in dried blood spot: an observational study in Brazilian patients.
    Varela P; Mastroianni Kirsztajn G; Motta FL; Martin RP; Turaça LT; Ferrer HLF; Gomes CP; Nicolicht P; Mara Marins M; Pessoa JG; Braga MC; D'Almeida V; Martins AM; Pesquero JB
    Orphanet J Rare Dis; 2020 Jan; 15(1):30. PubMed ID: 31996269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a rare disease registry for establishing phenotypic classification of previously unassigned
    Germain DP; Oliveira JP; Bichet DG; Yoo HW; Hopkin RJ; Lemay R; Politei J; Wanner C; Wilcox WR; Warnock DG
    J Med Genet; 2020 Aug; 57(8):542-551. PubMed ID: 32161151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution.
    Togawa T; Tsukimura T; Kodama T; Tanaka T; Kawashima I; Saito S; Ohno K; Fukushige T; Kanekura T; Satomura A; Kang DH; Lee BH; Yoo HW; Doi K; Noiri E; Sakuraba H
    Mol Genet Metab; 2012 Apr; 105(4):615-20. PubMed ID: 22305854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.